Evolution of the Polypill Concept and Ongoing Clinical Trials

被引:16
|
作者
Castellano, Jose M. [1 ]
Sanz, Gines [2 ]
Fuster, Valentin [1 ]
机构
[1] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA
[2] Natl Ctr Cardiovasc Res, Madrid, Spain
基金
欧盟第七框架计划;
关键词
CARDIOVASCULAR-DISEASE PREVENTION; SECONDARY PREVENTION; INCOME COUNTRIES; MIDDLE-INCOME; HIGH-RISK; ADHERENCE; STRATEGY; THERAPY; IMPACT; DRUGS;
D O I
10.1016/j.cjca.2014.02.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ischemic heart disease and stroke are the leading causes of death worldwide. What was once thought to be an endemic disease of high income countries has become a global epidemic, as low and middle income countries have adopted Western lifestyles, to the point that noncommunicable diseases are now the main cause of death in these regions, above and beyond communicable diseases, malnutrition, and injury. As a result, a large proportion of individuals at high 10-year risk of a cardiovascular event live in low- and middle-income countries, and the most of all cardiovascular events occur in developing countries. A large amount of evidence supports the use of pharmacological treatment for the prevention of cardiovascular death in this population, including antiplatelet drugs, beta-blockers, lipid-lowering agents, and angiotensin-converting enzyme inhibitors, however, the efficacy of cardiovascular event prevention is hampered by several problems, including inadequate prescription of medication, poor adherence to treatment, limited availability of medications, and unaffordable cost of treatment. Here we examine the use of fixed-dose combination therapy, and how this therapy could improve adherence to treatment, reduce the cost, and improve treatment affordability in low-income countries.
引用
收藏
页码:520 / 526
页数:7
相关论文
共 50 条
  • [31] Correlation of polypill and blood pressure level: A systematic review of clinical trials
    Omrani, Hamidreza
    Bahremand, Mostafa
    Keshavarzi, Fatemeh
    Solouki, Leila
    Zereshki, Ehsan
    JOURNAL OF EDUCATION AND HEALTH PROMOTION, 2023, 12 (01) : 171
  • [32] TAKING THE POLYPILL CONCEPT FORWARD
    Wald, N.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [33] Ongoing Clinical Trials of Nonviral siRNA Therapeutics
    Narasipura, Eshan A.
    VanKeulen-Miller, Rachel
    Ma, Yutian
    Fenton, Owen S.
    BIOCONJUGATE CHEMISTRY, 2023, 34 (07) : 1177 - 1197
  • [34] ONGOING CLINICAL TRIALS OF THE STATIN/EZETIMIBE COMBINATION
    Braunwald, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [35] Overview on ongoing or planned clinical trials in Europe
    Favaretto, A
    LUNG CANCER, 2005, 49 : S117 - S121
  • [36] Ongoing clinical trials and future trends of APBI
    Wazer, D.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S59 - S60
  • [37] Immunotherapy for lung cancer: ongoing clinical trials
    Declerck, Sarah
    Vansteenkiste, Johan
    FUTURE ONCOLOGY, 2014, 10 (01) : 91 - 105
  • [38] Translational gap in ongoing clinical trials for glioma
    Guishard, Alecia Florence
    Yakisich, Juan Sebastian
    Azad, Neelam
    Iyer, Anand Krishnan V.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2018, 47 : 28 - 42
  • [39] Ongoing clinical trials of the pleiotropic effects of statins
    Davignon, Jean
    Leiter, Lawrence
    VASCULAR HEALTH AND RISK MANAGEMENT, 2005, 1 (01) : 29 - 40
  • [40] Clinical trials in systemic lupus erythematosus: a status report on ongoing trials
    Gumber, Divya
    Paul, Jisna
    Ranganathan, Prabha
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (12) : 1633 - 1638